Linking whole‑brain EEG patterns to changes in consciousness during anesthesia

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective, single‑center observational cohort of about 250 adults (≥18 years, ASA I–III, MMSE ≥24, BMI ≤30) undergoing elective surgery at Tongji Hospital who will receive one of five intravenous induction agents chosen by their clinicians. High‑density 32‑channel EEG, BIS values, and behavioral state assessments using the MOAA/S scale will be recorded continuously during induction, with preoperative cognitive testing performed before anesthesia. Researchers blinded to group allocation will extract dynamic EEG features and develop models to identify drug‑agnostic biomarkers of anesthetic depth and a universal assessment algorithm that addresses known BIS limitations. No experimental drugs or departures from standard clinical care are involved.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age ≥ 18 years.
2. Scheduled to undergo elective surgery requiring general anesthesia with endotracheal intubation or laryngeal mask airway (LMA).
3. American Society of Anesthesiologists (ASA) Physical Status Class I to III.
4. Preoperative Mini-Mental State Examination (MMSE) score ≥ 24, indicating normal cognitive function.
5. Body mass index (BMI) ≤ 30 kg/m².
6. Ability to understand the study and provide written informed consent.

Exclusion Criteria:

1. History of drug abuse or dependence.
2. Known major neurological disorders (e.g., epilepsy, stroke, neurodegenerative diseases).
3. History of major psychiatric disorders.
4. Known or suspected pregnancy.
5. Inability to provide informed consent due to cognitive impairment, language barrier, or any other reason.

Where it's running

• Department of Anaesthesiology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology
  Wuhan, Hubei, China Recruiting

Study contacts

• Principal investigator: Pu Zhou, PhD. — Huazhong University of Science and Technology
• Study coordinator: Hua Zheng, MD. & PhD.
• Email: hzheng@hust.edu.cn
• Phone: 0086-27-83663173

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Two-hand face-mask hold (C-E vs V-E) during general anesthesia

  This will test whether the two-hand C-E or V-E face-mask hold helps adults under general anesthesia breathe more effectively.

  Recruiting at 2 sites Universidad de Antioquia · Medellín, Antioquia and 1 other locations · NCT07179432

• Autonomous Dual-Arm Breast Ultrasound: Scanning Performance and Diagnostic Agreement

  This study tests an autonomous dual-arm robotic breast ultrasound system to see if its scans and diagnostic impressions match those from conventional handheld ultrasound in adults undergoing breast screening.

  Recruiting at 3 sites Huazhong University of Science and Technology · Shiyan, Hubei and 3 other locations · NCT07915050

• QLESP Block vs PENG+LFCN Block for Total Hip Arthroplasty

  This trial tests whether the QLESP nerve block provides better pain relief after hip replacement than the standard PENG+LFCN blocks.

  Recruiting Huazhong University of Science and Technology · Wuhan, Hubei · NCT07771829

• QLESP Block to Ease Pain After Robot-Assisted Kidney Surgery

  Doctors are testing a ultrasound-guided nerve block called QLESP to see if it lowers pain and reduces strong pain medicines after robotic partial nephrectomy in adults.

  Recruiting Huazhong University of Science and Technology · Wuhan, Hubei · NCT07704970

• Ciprofol and Fentanyl for LMA Insertion in Children: Finding the ED95 Dose

  This study tests the smallest effective single dose of ciprofol, given with fentanyl, to help placing a laryngeal mask airway in children aged 1–12 undergoing anesthesia.

  Recruiting Phase 4 Huazhong University of Science and Technology · Wuhan, Hubei · NCT07697404

• First-line treatment for biliary tract cancer with iparomlimab, toripalimab, bevacizumab and chemotherapy

  This study tests a combination of iparomlimab and toripalimab with bevacizumab and chemotherapy as the first treatment approach for advanced biliary tract cancer.

  Recruiting Phase 4 Huazhong University of Science and Technology · Wuhan, Hubei · NCT07619235

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.